PS
PeptideScholar
Structured page family:Cost guide

Tirzepatide Cost Guide: Zepbound, Mounjaro, Coverage and Savings

In the United States, tirzepatide costs depend on whether the prescription is routed through Zepbound or Mounjaro pathways, the indication, the dose, and whether you qualify for official coverage or self-pay offers.

Active Market
This page is designed for US treatment decisions and uses US-first pricing and savings sources.
Official pricing
Use official Lilly pricing and savings pages as the starting point. Tirzepatide pricing can vary by brand, dose, device format, and whether you are using a savings card or a self-pay purchase program.
Cash-pay reality
Official self-pay programs now create dose-specific cash pricing for some Zepbound presentations, but the exact monthly amount still depends on dose and fulfillment path.
Insurance coverage
Coverage remains highly plan-dependent. Weight-management access often differs from diabetes coverage, and approved use does not guarantee a simple covered pathway.
Savings and coupons
Official Zepbound savings options may reduce cost for eligible patients with commercial coverage, and Lilly also publishes self-pay program terms for certain presentations.
Prior Authorization
Expect prior authorization or utilization management when tirzepatide is routed through obesity coverage, employer exclusions, or specialty-pharmacy workflows.

Need help comparing tirzepatide paths?

Use the provider matcher to package treatment interest, insurance, budget, urgency, and state context before you commit to a prescribing path.

Find a tirzepatide provider
Trust Summary
Reviewed 2026-04-11 by PeptideScholar editorial review. This page currently cites 3 official sources.
Tirzepatide offers, dose-specific self-pay pricing, and insurance rules can change. Verify every current figure directly on official Lilly pages before acting.

Tirzepatide Cost FAQ

Sources

  1. 1. Savings Options | Zepbound (tirzepatide)
    Zepbound • 2026
    Claim type: pricing
    View source →
  2. 2. FDA Approves First Medication for Obstructive Sleep Apnea
    FDA • 2024-12-20
    Claim type: regulatory
    View source →
  3. 3. Lilly releases Zepbound single-dose vials, expanding supply and access
    Eli Lilly and Company • 2024-08-27
    Claim type: pricing
    View source →

This content is for informational purposes only and does not constitute medical advice.